ICH
ICH Q7 19.40
19. AGENTS, BROKERS, TRADERS, DISTRIBUTORS, REPACKERS, AND RELABELLERS
Section text
Raw materials used in production of APIs for use in clinical trials should be evaluated by testing, or received with a supplier’s analysis and subjected to identity testing. When a material is considered hazardous, a supplier's analysis should suffice.
Source: International Council for Harmonisation (ICH) · © ICH. Per the legal notice in each guideline, the document may be used, reproduced and distributed provided ICH's copyright is acknowledged; any adaptation or translation must be labelled as such and must not imply ICH endorsement. · retrieved 2026-11-15